https://orcid.org/0000-0003-2062-7225
References
- Tennison I, Roschnik S, Ashby B, et al. Health care’s response to climate change: a carbon footprint assessment of the NHS in England. Lancet Planet Heal. 2021;5(2):e84–e92.
- D'Amato G, Cecchi L, D'Amato M, et al. Climate change and respiratory diseases. Eur Respir Rev. 2014; 23(132):700–169.
- British Thoracic Society. Position Statement: The Environment and Lung Health 2020. Available at: https://www.brit-thoracic.org.uk/document-library/governance-and-policy-documents/position-statements/environment-and-lung-health-position-statement-2020. [Date last accessed 29/04/2022]
- National Institute of Health and Care Excellence (NICE). NICE encourages use of greener asthma inhalers. Available at: https://www.nice.org.uk/news/article/nice-encourages-use-of-greener-asthma-inhalers. [Date last accessed 29/04/2022]
- Usmani OS, Scullion J, Keeley D. Our planet or our patients-is the sky the limit for inhaler choice? Lancet Respir Med. 2019;7(1):11–13.
- Kponee-Shovein K, Marvel J, Ishikawa R, et al. Carbon footprint associated costs of asthma exacerbation care among UK adults. J Med Econ. 2022;25(1):524–531.
- Sustainable Healthcare Coalition. Sustainable Care Pathways Guidance. Available at: https://shcoalition.org/sustainable-care-pathways-guidance/. [Date last accessed 29/04/2022]
- Woodcock A, Janson C, Rees J, et al. Effects of switching from a metered dose inhaler to a dry powder inhaler on climate emissions and asthma control: post-hoc analysis. Thorax. 2022. DOI:10.1136/thoraxjnl-2021-218088
- Reddel HK, FitzGerald JM, Bateman ED, et al. GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. Eur Respir J. 2019;53(6):1901046.
- Hatter L, Bruce P, Braithwaite I, et al. ICS-formoterol reliever versus ICS and short-acting β 2 -agonist reliever in asthma: a systematic review and Meta-analysis. ERJ Open Res. 2021;7(1):00701-2020. Published online
- Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent Asthma: A Systematic Review and Meta-analysis. JAMA. 2018;319(14):1485–1496.
- Beasley R, Harrison T, Peterson S, et al. Evaluation of Budesonide-Formoterol for maintenance and reliever therapy among patients with poorly controlled Asthma: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022;5(3):e220615.
- Beasley R, Holliday M, Reddel HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020–2030.
- Bloom CI, Nissen F, Douglas IJ, et al. Exacerbation risk and characterisation of the UK's asthma population from infants to old age. Thorax. 2018;73(4):313–320.
- McNamara D, Asher I, Davies C, et al. Asthma and respiratory foundation NZ. New Zealand child asthma guidelines: a quick reference guide. N Z Med J. 2017;130(1466):10–33.
- AstraZeneca. AstraZeneca progresses Ambition Zero Carbon programme with Honeywell partnership to develop next-generation respiratory inhalers. Available at: https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-progresses-ambition-zero-carbon-programme-with-honeywell-partnership-to-develop-next-generation-respiratory-inhalers.html. [Date last accessed 29/04/2022]
- Bisgaard H, Le Roux P, Bjåmer D, et al. Budesonide/formoterol maintenance plus reliver therapy: a new strategy in pediatric asthma. Chest. 2006;130(6):1733–1743.
- O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;171(2):129–136.
- Wilkinson AJK, Braggins R, Steinbach I, et al. Costs of switching to low global warming potential inhalers. An economic and carbon footprint analysis of NHS prescription data in England. BMJ Open. 2019;9(10):e028763–8.